Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room.

OBJECTIVES This study sought to report our experience with a routine completion angiogram after coronary artery bypass surgery (CABG) and simultaneous (1-stop) percutaneous coronary intervention (PCI) at the time of CABG performed in the hybrid catheterization laboratory/operating room. BACKGROUND The value of a routine completion angiogram after CABG and 1-stop hybrid CABG/PCI remains unresolved. METHODS Between April 2005 and July 2007, 366 consecutive patients underwent CABG surgery, with (n = 112) or without (n = 254) concomitant 1-stop PCI (hybrid), all with completion angiography before chest closure. Among the 112 1-stop hybrid CABG/PCI patients, 67 (60%) underwent a planned hybrid procedure based on pre-operative assessment, whereas 45 (40%) underwent open-chest PCI (unplanned hybrid) based on intraoperative findings. RESULTS Among the 796 CABG grafts (345 left internal mammary artery, 12 right internal mammary artery/radial, and 439 veins), 97 (12%) angiographic defects were identified. Defects were repaired with either a minor adjustment of the graft (n = 22, 2.8%), with intraoperative open-chest PCI (unplanned hybrid, n = 48, 6%) or with traditional surgical revision (n = 27, 3.4%). Hybrid patients had clinical outcomes similar to standard CABG patients. CONCLUSIONS Routine completion angiography detected 12% of grafts with important angiographic defects. One-stop hybrid coronary revascularization is reasonable, safe, and feasible. Combining the tools of the catheterization laboratory and operating room greatly enhances the options available to the surgeon and cardiologist for patients with complex coronary artery disease.

[1]  G. Feuchtner,et al.  Risk factors of postoperative nephropathy in patients undergoing innovative CABG and intraoperative graft angiography. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  Bari Investigators.  The final 10-year follow-up results from the BARI randomized trial. , 2007 .

[3]  Prevent Iv Investigators.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[4]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[5]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[6]  D. Taggart,et al.  Intraoperative imaging techniques to assess coronary artery bypass graft patency. , 2007, The Annals of thoracic surgery.

[7]  A. Colombo,et al.  Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease) , 2007, Circulation.

[8]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[9]  Jin Li-jun,et al.  The final 10-year follow-up results from the BARI randomized trial. , 2007, Journal of the American College of Cardiology.

[10]  Ameet Bakhai,et al.  Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial , 2002, The Lancet.

[11]  P. Serruys,et al.  Drug-Eluting Stent Update 2007: Part II: Unsettled Issues , 2007, Circulation.

[12]  H. Nathoe,et al.  A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients☆ , 2003 .

[13]  Richard Tran,et al.  Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass. , 2008, The Journal of thoracic and cardiovascular surgery.

[14]  S. Pauker,et al.  A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. , 2003, Journal of the American College of Cardiology.

[15]  K M Taylor,et al.  The platelet in cardiopulmonary bypass. , 1998, The Annals of thoracic surgery.

[16]  G. Angelini,et al.  Hybrid coronary revascularization in the era of drug-eluting stents. , 2004, The Annals of thoracic surgery.

[17]  W. C. Sheldon,et al.  Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. , 1986, The New England journal of medicine.

[18]  최동훈,et al.  A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis , 2003 .

[19]  R. Califf,et al.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005, JAMA.

[20]  L. Finch.  A hybrid approach , 1998 .

[21]  Patrick W Serruys,et al.  Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. , 2005, Journal of the American College of Cardiology.

[22]  F. Loop,et al.  The effect of coronary reoperation on the survival of patients with stenoses in saphenous vein bypass grafts to coronary arteries. , 1993, The Journal of thoracic and cardiovascular surgery.

[23]  E. Hannan,et al.  Drug-Eluting Stents vs Coronary-Artery Bypass Grafting in Multivessel Coronary Disease , 2008 .

[24]  G. Breithardt,et al.  Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. , 2006, The American journal of cardiology.

[25]  R. de Caterina,et al.  Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. , 2004, European heart journal.

[26]  L. Cohn,et al.  Staged initial percutaneous coronary intervention followed by valve surgery ("hybrid approach") for patients with complex coronary and valve disease. , 2004, Journal of the American College of Cardiology.

[27]  M. Carrier,et al.  Quantitative angiographic assessment of coronary anastomoses performed without cardiopulmonary bypass. , 1999, The Journal of thoracic and cardiovascular surgery.

[28]  N. Smedira,et al.  A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. , 2006, Journal of Thoracic and Cardiovascular Surgery.

[29]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.